Serina Therapeutics, Inc.
SER · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | -100% | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 87.7% | – | 100% |
| R&D Expenses | $4 | $3 | $3 | $2 |
| G&A Expenses | $0 | $3 | $0 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $6 | $6 | $6 | $6 |
| Operating Income | -$6 | -$6 | -$6 | -$6 |
| % Margin | – | -4,280.8% | – | 39,635.7% |
| Other Income/Exp. Net | $2 | -$1 | $1 | $3 |
| Pre-Tax Income | -$5 | -$6 | -$5 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$6 | -$5 | -$3 |
| % Margin | – | -4,960% | – | 19,571.4% |
| EPS | -0.444 | -0.64 | -0.493 | -0.31 |
| % Growth | 30.7% | -29.7% | -59.1% | – |
| EPS Diluted | -0.444 | -0.64 | -0.493 | -0.25 |
| Weighted Avg Shares Out | 10 | 10 | 10 | 9 |
| Weighted Avg Shares Out Dil | 10 | 10 | 10 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$6 | -$5 | -$3 |
| % Margin | – | -4,951.5% | – | 19,135.7% |